Integrated BioPharma, Inc.

OTCPK:INBP Stock Report

Market Cap: US$6.7m

Integrated BioPharma Past Earnings Performance

Past criteria checks 0/6

Integrated BioPharma's earnings have been declining at an average annual rate of -15.1%, while the Personal Products industry saw earnings growing at 14.8% annually. Revenues have been declining at an average rate of 0.09% per year.

Key information

-15.1%

Earnings growth rate

-15.6%

EPS growth rate

Personal Products Industry Growth20.9%
Revenue growth rate-0.09%
Return on equity-0.6%
Net Margin-0.2%
Last Earnings Update31 Mar 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Integrated BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:INBP Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2451040
31 Dec 2351040
30 Sep 2351040
30 Jun 2351040
31 Mar 2351140
31 Dec 2253240
30 Sep 2256340
30 Jun 2256440
31 Mar 2260740
31 Dec 2161740
30 Sep 2161740
30 Jun 2164840
31 Mar 2160540
31 Dec 2057540
30 Sep 2057530
30 Jun 2053430
31 Mar 2053340
31 Dec 1953340
30 Sep 1951240
30 Jun 1950240
31 Mar 1949230
31 Dec 1845230
30 Sep 1844130
30 Jun 1844130
31 Mar 1842130
31 Dec 1742130
30 Sep 1744230
30 Jun 1747230
31 Mar 1747230
31 Dec 1647130
30 Sep 1645130
30 Jun 1642130
31 Mar 1640030
31 Dec 1538030
30 Sep 1538130
30 Jun 1537130
31 Mar 1537130
31 Dec 1435030
30 Sep 1433030
30 Jun 1434030
31 Mar 1435140
31 Dec 1336140
30 Sep 1334140
30 Jun 1334040

Quality Earnings: INBP is currently unprofitable.

Growing Profit Margin: INBP is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: INBP is unprofitable, and losses have increased over the past 5 years at a rate of 15.1% per year.

Accelerating Growth: Unable to compare INBP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INBP is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (6.9%).


Return on Equity

High ROE: INBP has a negative Return on Equity (-0.61%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.